Keros Therapeutics, Inc.

We are a clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. We specialize in understanding the role of TGF-ß proteins, which regulate the growth, repair, and maintenance of tissues such as skeletal muscle, bone, adipose, heart tissue, and blood. Using this knowledge, we have discovered and are developing protein therapeutics. Our lead product candidate, rinvatercept (KER-065), is being developed for neuromuscular diseases. Rinvatercept is designed to bind to and inhibit TGF-ß ligands, including myostatin (GDF8) and activin A, which negatively regulate muscle and bone mass and strength. We are developing rinvatercept for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). In March 2025, we announced initial topline results from the Phase 1 clinical trial of rinvatercept in healthy adult volunteers. Our most advanced product candidate, elritercept (KER-050), is being developed for low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis. In December 2024, we entered into an exclusive license agreement with Takeda Pharmaceuticals U.S.A., Inc. (Takeda) to further develop, manufacture, and commercialize elritercept worldwide outside of mainland China, Hong Kong, and Macau. This agreement became effective on January 16, 2025.